Company Name
Avadel Pharmaceuticals PLC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN:
IE00BDGMC594
CIK:
0001012477
CUSIP:
338488109
Currency:
USD
Full Time Employees:
188
Phone:
353 1 901 5201
Website:
https://www.avadel.com
Fiscal Year End:
December
IPO Date:
Jun 07, 1996
Description:
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Address:
10 Earlsfort Terrace, Dublin, Ireland, D02 T380